According to the latest study from BCC Research, "The Global Influenza Market" is expected to grow from $9.0 billion in 2024 ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Amid the sultry summer months, a few signs of fall become apparent, such as the appearance of school supplies on stores ...

Respiratory syncytial virus (RSV) infections were associated with significantly increased risk for complications beyond ...

Shares of GSK rose on Thursday after the company announced it had begun shipping its seasonal flu vaccines, Fluarix and ...

The disease was found following tests on a severely emaciated doe that was euthanized and tested in early June, Andrea Korman ...

Susman shared Tuesday that she’ll be stepping down from her role as EVP and chief corporate affairs officer after 18 years with the company. Susman joined Pfizer in 2007 and helped lead the company ...

As if to address the concerns of both groups, Kennedy's FDA announced in May that it approves covid boosters only for those ...

British regulators issued the alert for two versions of a jab given to millions of pensioners and pregnant women after ...

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the ...